T-Mobile Us Inc (TMUS) Stock Price Today
Aura AI Summary
Key Stats
- $196.71BMarket Cap
- -Volume
- MediaSector
- $259.0152W High
- $167.6552W Low
- -Typical Hold Time
- $313.32BEnterprise Value
- 2.22%Div Yield
- -Trading Activity
Track T-Mobile Us Inc (TMUS) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, T-Mobile Us Inc has traded between a low of $167.65 and a high of $259.01, highlighting its annual price range. Buy and sell T-Mobile Us Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Most Recent News
Major stocks fall sharply amid mixed earnings and negative outlooks, signaling broader market concerns.
Several leading stocks, including SoundThinking, TSS, and ADI Global Distribution, dropped significantly due to factors like lowered revenue forecasts and disappointing quarterly results. SoundThinking fell over 25% after cutting its revenue outlook ...
Definitive Healthcare posts a stellar 41.44% ROIC, far surpassing its 5.78% capital cost.
Definitive Healthcare Corp. stands out with a remarkable Return on Invested Capital (ROIC) of 41.44%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.78%. This means the company generates over seven times the value for every ...
Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.